



# FAIRCHEM ORGANICS LIMITED

Works & Office : 253/P & 312, Village Chekhala, Sanand - Kadi Highway,  
Taluka : SANAND, Dist.: Ahmedabad 382 115, INDIA.  
Phone (Board Nos.) : (02717) 687900, 687901, +91 90163 24095  
E-mail : cs@fairchem.in  
CIN : U24200MH2019PLC323176 Website : www.fairchem.in

Date: August 02, 2021

To,  
**National Stock Exchange of India Ltd.**  
Exchange Plaza,  
Plot no. C/1, G Block, Bandra-kurla Complex  
Bandra (E)  
Mumbai – 400 051.

To,  
**Department of Corporate Services,  
BSE Limited.**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001.

**BSE Code: 543252 and NSE Symbol: 'FAIRCHEMOR'**

Dear Sirs,


**Sub.: Investor Presentation.**

Pursuant to Regulation 30 and other applicable regulations of SEBI (LODR) Regulations, 2015 we are uploading herewith a PDF file containing Earning presentation prepared post first quarter financial results of the Company. Please note that we did not have any analyst/institutional investors meet and so have not shared this presentation with any one.

Please find the above in order and take the same on your record.

Thanking you,

Yours faithfully,  
For Fairchem Organics Limited,

  
Rajen Jhaveri  
Chief Financial Officer & Company Secretary  
Encl: as above

# Fairchem Organics Limited



## Earnings Presentation

Q1-FY22



# Company at a Glance

25 years of legacy

Long lasting Pan India  
Raw Material sourcing  
capabilities with  
diversified vegetable  
oil refineries

Well entrenched  
Customer  
Relationships in high  
growth industries like  
Paint, Inks, Printing

Promoted by Fairfax  
India Holdings and  
backed by  
experienced  
Management team

Ongoing Capacity  
expansion to increase  
capacity by more than  
2.5x by end of FY22  
with minimal CAPEX

Leading  
manufacturer in  
India for  
substantial part  
of the overall  
revenue

High emphasis on  
Business Sustainability  
and Corporate  
Governance standards

One of a kind  
manufacturing process  
using by-products of  
vegetable oils to create  
value added products hence  
creating Wealth  
from Waste

State-of-the-art  
manufacturing unit  
with critical  
equipment/design  
from Germany &  
Switzerland


Strong Return Ratios  
ROE: 25%  
ROCE: 30%

Strong Long Term  
Financial Track Record  
5 year CAGR:  
Revenue: 14%  
EBITDA: 24%  
PAT: 36%


# Company Overview

- Fairchem Organics Ltd. (Fairchem) is engaged in the business of manufacturing of Oleo Chemicals and Nutraceuticals, since the last 25 years.
- The company's key oleo chemical products include Dimer Acid, Linoleic Acid, Palmitic Acid, Monomer Acid, and nutraceutical products include Mixed Tocopherols and Sterol concentrate.
- It has a state -of-the-art Manufacturing unit which was set up in 1995 and has over the years gone through various stages of expansion, backward integration, debottlenecking and technological advancements to create a one of its kind world class facility.
- The plant raw material capacity has been expanded from 45,000 MTPA to 72,000 MTPA in FY21, and is being expanded further to 1,20,000 MTPA by end of FY22 with minimal capex spends.
- Fairchem is the one of the only manufacturers of Linoleic Acid and Dimer Acid in India, which are the major part of the overall revenues and having a large addressable market size in India.
- Mixed Tocopherol concentrate and Sterols concentrate are nutraceutical products having usage in FMCG and food additives.
- Fairchem supplies to various marquee customers like Asian Paints, Huber (erstwhile Micro Inks), Arkema, BASF, ADM, Cargill etc.

Revenue & EBITDA Margin (In Mn)



FY21 Segmental Revenue (%)



# Fairchem's Competitive Advantage

## Major Player in the Indian Oleo Chemical Market Using Renewable Resources

- Processing waste from edible oil refining process to produce high value oleo chemicals giving it price advantage
- Enjoy Leadership Position in the industry due to barriers to entry
- Focus on green manufacturing processes which reduces effluents to ensure sustainability

## Strong Customer and Supplier Relationships

- Well entrenched Customer Relationships in high growth industries like Paint, Inks, FMCG
- Fair pricing from customers due to quality of products
- More than 20 years relationship with key raw material suppliers.

## Competitive Position

- Low cost of raw material and efficient manufacturing process enables it to be highly cost competitive vis a vis global peers
- Leading manufacturer in India for substantial part of the overall revenue
- Position to sell most that it produces

## Experienced senior management

- Fairchem is well supported by an esteemed Promoter Institution – Fairfax India Holdings
- Strong and experienced management team that have positioned business well for continued growth and development
- Strong R&D team focusing on integration and green chemistry

## Capital Efficiency

- Majority of the capacity expansion has been undertaken primarily through internal accruals.
- Judicious strategy on capacity expansion by evaluating market demand-supply scenario and working very closely with its customer base

# Financial Governance Standards

Invest for long term growth value creation

Always be adequately capitalized

Not overleverage the balance sheet

Secure sources of sustainable raw material supply

Invest in backward and forward integration

Transparent communications with all the stakeholders

Low volatility in the cash flow generation





## Key Financial Highlights

# Q1-FY22 Financial Highlights

## Q1-FY22 Financial Performance

**INR 1,391 Mn**  
Revenue from  
Operations

**INR 328 Mn**  
EBITDA

**23.58%**  
EBITDA Margins

**INR 223 Mn**  
PAT

**16.03%**  
PAT Margins

**INR 17.14/Share**  
Diluted EPS

- The revenues for the quarter were impacted due to the second wave of Covid-19 pandemic
- The company's continuous efforts on manufacturing efficiency mainly on account of debottlenecking helped the Company in achieving better yields with greater efficiency
- Saving in interest cost on account of improved financial condition since last few months
- Reduction in Other Expenses mainly driven by lower Legal and Professional Fees as a major portion of such expenses pertaining to Demerger had accrued and was accounted for during the previous quarters



# Q1-FY22 Profit & Loss Statement

| PARTICULARS (INR Mn)                 | Q1-FY22       | Q1-FY21       | Y-O-Y     | Q4-FY21       | Q-O-Q          |
|--------------------------------------|---------------|---------------|-----------|---------------|----------------|
| Revenue from Operations              | 1,391         | 351           | 296.3%    | 1,593         | (12.7)%        |
| Total Expenses                       | 1,063         | 307           | NA        | 1,319         | (19.4)%        |
| EBITDA                               | 328           | 44            | NA        | 274           | 19.7%          |
| <i>EBITDA Margin</i>                 | <i>23.58%</i> | <i>12.54%</i> | <i>NA</i> | <i>17.20%</i> | <i>638 bps</i> |
| Other Income                         | 4             | -             | NA        | 3             | (33.3)%        |
| Depreciation                         | 17            | 16            | 6.3%      | 16            | 6.3%           |
| Finance Cost                         | 16            | 15            | 6.7%      | 21            | 23.8%          |
| PBT                                  | 299           | 13            | NA        | 240           | 24.6%          |
| Tax                                  | 76            | 1             | NA        | 52            | 46.2%          |
| Profit After Tax                     | 223           | 12            | NA        | 188           | 18.6%          |
| <i>PAT Margin</i>                    | <i>16.03%</i> | <i>3.42%</i>  | <i>NA</i> | <i>11.80%</i> | <i>423 bps</i> |
| Other Comprehensive Income           | (1)           | (1)           | NA        | (4)           | NA             |
| Total Comprehensive Income           | 222           | 11            | NA        | 184           | 20.7%          |
| Basic/Diluted EPS<br>(INR per share) | 17.14         | 0.92          | NA        | 14.46         | 18.5%          |

# Historical Profit & Loss Statement

| PARTICULARS (INR Mn)              | FY19          | FY20          | FY21          | Q1-FY22       |
|-----------------------------------|---------------|---------------|---------------|---------------|
| Revenue from Operations           | 2,499         | 3,065         | 3,966         | 1,391         |
| Total Expenses                    | 2,138         | 2,581         | 3,279         | 1,063         |
| <b>EBITDA</b>                     | <b>361</b>    | <b>484</b>    | <b>687</b>    | <b>328</b>    |
| <b>EBITDA Margin</b>              | <b>14.44%</b> | <b>15.79%</b> | <b>17.32%</b> | <b>23.58%</b> |
| Other Income                      | 43            | 66            | 3             | 4             |
| Depreciation                      | 55            | 60            | 66            | 17            |
| Finance Cost                      | 57            | 66            | 68            | 16            |
| <b>PBT</b>                        | <b>292</b>    | <b>424</b>    | <b>556</b>    | <b>299</b>    |
| Tax                               | 77            | 77            | 131           | 76            |
| <b>Profit After Tax</b>           | <b>215</b>    | <b>347</b>    | <b>425</b>    | <b>223</b>    |
| <b>PAT Margin</b>                 | <b>8.60%</b>  | <b>11.32%</b> | <b>10.72%</b> | <b>16.03%</b> |
| Other Comprehensive Income        | (2)           | (1)           | (5)           | (1)           |
| <b>Total Comprehensive Income</b> | <b>213</b>    | <b>346</b>    | <b>420</b>    | <b>222</b>    |
| Basic/Diluted EPS (INR per share) | 5.51          | 26.65         | 32.63         | 17.14         |

# Historical Balance Sheet

| ASSETS                        | FY19         | FY20         | FY21         | EQUITY AND LIABILITIES                | FY19         | FY20         | FY21         |
|-------------------------------|--------------|--------------|--------------|---------------------------------------|--------------|--------------|--------------|
| <b>Non-Current Assets</b>     |              |              |              | <b>EQUITY</b>                         |              |              |              |
| Property, Plant and Equipment | 1,108        | 1,219        | 1,220        | Equity Share Capital                  | 391          | 130          | 130          |
| Capital work-in-progress      | 9            | 94           | 295          | Instruments entirely equity in nature |              |              |              |
| Right of use assets           | 44           | 43           | 43           | Other Equity                          | 635          | 1,137        | 1,557        |
| Intangible Assets             | -            | 1            | -            |                                       | <b>1,026</b> | <b>1,267</b> | <b>1,687</b> |
| Financial Assets              |              |              |              | <b>LIABILITIES</b>                    |              |              |              |
| (i) Investments               | -            | -            | -            | <b>Non-Current Liabilities</b>        |              |              |              |
| (ii) Loans                    | -            | -            | -            | Financial Liabilities                 |              |              |              |
| (iii) Other Financial Assets  | 1            | 3            | -            | Borrowings                            | 83           | 163          | 260          |
| Non-current Tax Assets (Net)  | 6            | 14           | 18           | Provisions                            | 9            | 12           | 18           |
| Other Non-current Assets      | 13           | 66           | 30           | Deferred Tax Liabilities (Net)        | 121          | 116          | 113          |
|                               | <b>1,181</b> | <b>1,440</b> | <b>1606</b>  |                                       | <b>213</b>   | <b>291</b>   | <b>391</b>   |
| <b>Current Assets</b>         |              |              |              | <b>Current Liabilities</b>            |              |              |              |
| Inventories                   | 340          | 353          | 453          | Financial Liabilities                 |              |              |              |
| Financial Assets              |              |              |              | (i) Borrowings                        | 405          | 444          | 222          |
| (i) Trade receivables         | 321          | 379          | 468          | (ii) Trade Payables                   | 100          | 64           | 109          |
| (ii) Cash and Bank Balance    | 2            | 2            | 4            | (iii) Other financial liabilities     | 93           | 81           | 107          |
| (iv) Loans                    | -            | -            | -            | Other current liabilities             | 28           | 29           | 46           |
| (v) Other Financial Assets    | -            | -            | -            | Provisions                            | 6            | 3            | 10           |
| Other current assets          | 33           | 15           | 55           | Current Tax Liabilities (Net)         | 6            | 10           | 14           |
|                               | <b>696</b>   | <b>749</b>   | <b>980</b>   |                                       | <b>638</b>   | <b>631</b>   | <b>508</b>   |
| <b>TOTAL ASSETS</b>           | <b>1,877</b> | <b>2,189</b> | <b>2,586</b> | <b>TOTAL EQUITY AND LIABILITIES</b>   | <b>1,877</b> | <b>2,189</b> | <b>2,586</b> |



# Historical Cash Flow Statement


| PARTICULARS (INR Mn)                               | FY19  | FY20  | FY21  |
|----------------------------------------------------|-------|-------|-------|
| Cash and Cash Equivalents at Beginning of the year | 0.2   | 0.2   | 0.3   |
| Cash Flow From Operating Activities                | 342   | 312   | 394   |
| Cash Flow from Investing Activities                | (137) | (239) | (228) |
| Cash Flow From Financing Activities                | (205) | (73)  | (166) |
| Net Inc./ (Dec.) in Cash and Cash Equivalent       | -     | -     | -     |
| Cash and Cash Equivalents at End of the year       | 0.2   | 0.2   | 0.3   |
| Operating Cash Inflow                              | 342   | 312   | 394   |
| Capital Expenditure                                | (177) | (303) | (231) |
| FCF                                                | 165   | 9     | 163   |

# Key Financial Highlights


## Revenue (In Mn)




## EBITDA (In Mn) & EBITDA Margin (%)




## PAT (In Mn) & PAT Margin (%)




## Net Debt to Equity




## Cash Conversion Cycle Days





## Return Ratios



# Capital Markets



| Price Data as at June 30 <sup>th</sup> , 2021 | INR             |
|-----------------------------------------------|-----------------|
| Face Value                                    | 10.00           |
| Market Price                                  | 1,468.9         |
| 52 Week H/L                                   | 1,768.9 / 511.0 |
| Market Cap (Mn)                               | 19,126.4        |
| Equity Shares Outstanding (Mn)                | 13.0            |
| 1 Year Avg Trading Volume ('000)              | 49.8            |





# Disclaimer

## Fairchem Organics Limited Disclaimer:

*The information contained in this presentation is only current as of its date. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. There is no representation that all information relating to the context has been taken care off in the presentation and neither we undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise. We will accept no liability whatsoever for any loss arising directly or indirectly from the use of, reliance of any information contained in this presentation or for any omission of the information. The information shall not be distributed or used by any person or entity in any jurisdiction or countries were such distribution or use would be contrary to the applicable laws or Regulations. It is advised that prior to acting upon this presentation independent consultation / advise may be obtained and necessary due diligence, investigation etc. may be done at your end. You may also contact us directly for any questions or clarifications at our end. This presentation contain certain statements of future expectations and other forward-looking statements, including those relating to our general business plans and strategy, our future financial condition and growth prospects, and future developments in our industry and our competitive and regulatory environment. In addition to statements which are forward looking by reason of context, the words 'may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, potential or continue and similar expressions identify forward looking statements. Actual results, performances or events may differ materially from these forward-looking statements including the plans, objectives, expectations, estimates and intentions expressed in forward looking statements due to a number of factors, including without limitation future changes or developments in our business, our competitive environment, telecommunications technology and application, and political, economic, legal and social conditions in India. It is cautioned that the foregoing list is not exhaustive This presentation is not being used in connection with any invitation of an offer or an offer of securities and should not be used as a basis for any investment decision*

## Valorem Advisors Disclaimer:

*Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.*

For further details, please feel free to contact our Investor Relations Representatives:



Mr. Anuj Sonpal  
Valorem Advisors  
Tel: +91-22-4903-9500  
Email: [fairchem@valoremadvisors.com](mailto:fairchem@valoremadvisors.com)